Literature DB >> 24613728

The TNF family in T cell differentiation and function--unanswered questions and future directions.

Michael Croft1.   

Abstract

Proteins in the TNF/TNFR superfamily are recognized as major regulators of the activity of conventional CD4 and CD8 T cells, and also of regulatory T cells (Treg). Stimulatory molecules such as OX40, CD27, GITR, DR3, CD30, 4-1BB, TACI, and TNFR2 can promote division and survival in T cells, enhance effector activity including cytokine production, and drive the generation of T cell memory. They also display the capacity to block the development of inducible Treg cells or inhibit suppressive activity in Treg cells. Additionally, molecules such as Fas, TNFR1, and TRAILR promote apoptotic death in T cells and generally limit T cell activity. Although our knowledge of these proteins is quite good at this point in time, there are still many unknowns regarding their function, their expression patterns, and the involvement of these different molecules at various stages of the T cell response that occurs in autoimmunity, cancer, infectious disease, and during vaccination. Importantly, it is still unresolved how similar or dissimilar each of these receptors are to one another, the extent to which cooperation occurs between family members, and whether alternate TNF-TNFR interactions induce qualitatively different cellular responses. All of the molecules are attractive targets for immunotherapy of human disease, but it is not yet clear how to differentiate between them and make an informed decision as to whether any one protein may be the preferred focus of clinical development for a given specific disease indication. This review will highlight unanswered questions related to these molecules and the biology of T cells, and describe possible future directions for research in this area. Expanding our knowledge of how the TNF/TNFR family control T cells will undoubtedly help fulfill the promise of these molecules for providing efficacious clinical therapy of immune system disease.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-1BB; CD27; GITR; HVEM; OX40; TNFR2

Mesh:

Substances:

Year:  2014        PMID: 24613728      PMCID: PMC4099277          DOI: 10.1016/j.smim.2014.02.005

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  47 in total

Review 1.  CD27 and CD70 in T cell and B cell activation.

Authors:  Jannie Borst; Jenny Hendriks; Yanling Xiao
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

2.  During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.

Authors:  Jenny Hendriks; Yanling Xiao; John W A Rossen; Koenraad F van der Sluijs; Kazuo Sugamura; Naoto Ishii; Jannie Borst
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

3.  From vanilla to 28 flavors: multiple varieties of T regulatory cells.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

4.  OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.

Authors:  Takanori So; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

Review 5.  How do pleiotropic kinase hubs mediate specific signaling by TNFR superfamily members?

Authors:  Bärbel Schröfelbauer; Alexander Hoffmann
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

6.  Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory.

Authors:  Fabrina M C Gaspal; Mi-Yeon Kim; Fiona M McConnell; Chandra Raykundalia; Vasilios Bekiaris; Peter J L Lane
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

Review 7.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

8.  Costimulation of human CD28- T cells by 4-1BB ligand.

Authors:  Jacob Bukczynski; Tao Wen; Tania H Watts
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

Review 9.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

10.  Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood.

Authors:  Minji Byun; Cindy S Ma; Arzu Akçay; Vincent Pedergnana; Umaimainthan Palendira; Jinjong Myoung; Danielle T Avery; Yifang Liu; Avinash Abhyankar; Lazaro Lorenzo; Monika Schmidt; Hye Kyung Lim; Olivier Cassar; Melanie Migaud; Flore Rozenberg; Nur Canpolat; Gönül Aydogan; Bernhard Fleckenstein; Jacinta Bustamante; Capucine Picard; Antoine Gessain; Emmanuelle Jouanguy; Ethel Cesarman; Martin Olivier; Philippe Gros; Laurent Abel; Michael Croft; Stuart G Tangye; Jean-Laurent Casanova
Journal:  J Exp Med       Date:  2013-07-29       Impact factor: 14.307

View more
  45 in total

1.  NFκB-Pim-1-Eomesodermin axis is critical for maintaining CD8 T-cell memory quality.

Authors:  Karin M Knudson; Curtis J Pritzl; Vikas Saxena; Amnon Altman; Mark A Daniels; Emma Teixeiro
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

2.  Neurocognitive Impairment as One Facet of Cancer-Related Sickness Behavior Symptoms.

Authors:  Carissa A Low; Pawel Kalinski; Dana H Bovbjerg
Journal:  J Natl Cancer Inst       Date:  2015-06-22       Impact factor: 13.506

3.  Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Authors:  Paurvi Shinde; Wenhai Liu; Antoine Ménoret; Andrew D Luster; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2017-04-21       Impact factor: 4.962

4.  Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells.

Authors:  Maria-Luisa del Rio; Carlos Fernandez-Renedo; Olivier Chaloin; Stefanie Scheu; Klaus Pfeffer; Yasushi Shintani; Jose-Antonio Perez-Simon; Pascal Schneider; Jose-Ignacio Rodriguez-Barbosa
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

5.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.

Authors:  Jose-Ignacio Rodriguez-Barbosa; Carlos Fernandez-Renedo; Ana María Bravo Moral; Leo Bühler; Maria-Luisa Del Rio
Journal:  Cell Mol Immunol       Date:  2016-02-29       Impact factor: 11.530

7.  HVEM Imprints Memory Potential on Effector CD8 T Cells Required for Protective Mucosal Immunity.

Authors:  Pritesh Desai; Georges Abboud; Jessica Stanfield; Paul G Thomas; Jianxun Song; Carl F Ware; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

8.  Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production.

Authors:  M-C Lu; C-L Yu; H-C Chen; H-C Yu; H-B Huang; N-S Lai
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

Review 10.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.